While many firms have been riding the bankruptcy wave to lucrative paydays, others are getting swamped by it. A relatively obscure filing for Chapter 7 liquidation by a small suburban Boston-based pharmaceutical company shows why.
On Monday, Dynogen Pharmaceuticals filed for Chapter 7 in U.S. Bankruptcy Court in Boston. The Boston Business Journal reports that the Waltham, Mass.-based company had raised $67 million in venture capital over the past six years.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
